QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:ALECAlector Stock Price, Forecast & News

$14.35
-0.18 (-1.24 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.09
Now: $14.35
$14.69
50-Day Range
$14.53
MA: $21.73
$30.20
52-Week Range
$13.26
Now: $14.35
$35.93
Volume1.10 million shs
Average Volume696,241 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.62
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALEC
CUSIPN/A
CIKN/A
Phone415-231-5660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.22 million
Book Value$2.83 per share

Profitability

Net Income$-105,390,000.00
Net Margins-556.70%

Miscellaneous

Employees91
Market Cap$1.13 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$14.35
-0.18 (-1.24 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alector (NASDAQ:ALEC) Frequently Asked Questions

How has Alector's stock price been impacted by Coronavirus (COVID-19)?

Alector's stock was trading at $24.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALEC shares have decreased by 42.4% and is now trading at $14.35.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Alector?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector
.

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Alector
.

How were Alector's earnings last quarter?

Alector Inc (NASDAQ:ALEC) issued its earnings results on Tuesday, August, 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.09. Alector had a negative net margin of 556.70% and a negative return on equity of 48.29%.
View Alector's earnings history
.

What price target have analysts set for ALEC?

8 Wall Street analysts have issued 12-month target prices for Alector's stock. Their forecasts range from $28.00 to $41.00. On average, they anticipate Alector's stock price to reach $32.80 in the next year. This suggests a possible upside of 128.6% from the stock's current price.
View analysts' price targets for Alector
.

Has Alector been receiving favorable news coverage?

Media headlines about ALEC stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alector earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Alector
.

Are investors shorting Alector?

Alector saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 5,630,000 shares, an increase of 12.6% from the January 31st total of 5,000,000 shares. Based on an average daily trading volume, of 593,100 shares, the days-to-cover ratio is presently 9.5 days. Currently, 12.6% of the company's stock are short sold.
View Alector's Short Interest
.

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Who are Alector's key executives?

Alector's management team includes the following people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
  • Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
  • Dr. Robert S. King, Chief Devel. Officer (Age 56)
  • Dr. Asa Abeliovich M.D., Ph.D., Co-Founder

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.24%), Goldman Sachs Group Inc. (0.70%), Cannell Peter B & Co. Inc. (0.26%), First Trust Advisors LP (0.18%), Alps Advisors Inc. (0.14%) and California Public Employees Retirement System (0.13%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector
.

Which institutional investors are selling Alector stock?

ALEC stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Russell Investments Group Ltd., Principal Financial Group Inc., Cannell Peter B & Co. Inc., and Virtus ETF Advisers LLC. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney, and Terrance Mcguire.
View insider buying and selling activity for Alector
.

Which institutional investors are buying Alector stock?

ALEC stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Swiss National Bank, First Trust Advisors LP, Goldman Sachs Group Inc., California Public Employees Retirement System, Barclays PLC, Rafferty Asset Management LLC, and New York State Common Retirement Fund. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector
.

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $14.35.

How big of a company is Alector?

Alector has a market capitalization of $1.13 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe.

What is Alector's official website?

The official website for Alector is www.alector.com.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.